Esperance’s business strategy is to focus on internal research and development strengths to validate product candidates through proof of concept in cancer patients. We offer access to discovery expertise and product candidates in areas of unmet medical need and distinct commercial value.
Esperance’s objective is to secure partnerships to enhance our combined ability to advance novel science and accelerate the development of differentiated therapeutics. Our broad intellectual property portfolio and unique research approach enable us to be a productive partner for those seeking to advance meaningful therapeutics in oncology and other core therapeutic areas.
In August 2015 Esperance announced a strategic alliance agreement with MD Anderson Cancer Center under the umbrella of Strategic Industry Ventures to advance the clinical development of EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer based on positive results from a Phase 2 trial of EP-100 in ovarian cancer patients resistant to paclitaxel (Taxol), the standard of care for this disease.
If interested in learning more, please contact:
President & CEO